Clinical trial • Phase III • Cardiology|Neurology|Rare Disease
acoramidis hydrochloride for Transthyretin amyloidosis | Transthyretin amyloid cardiomyopathy (ATTR-CM)
Phase III trial of acoramidis hydrochloride for Transthyretin amyloidosis | Transthyretin amyloid cardiomyopathy (ATTR-CM).
Overview
- Trial Therapeutic Area
- Cardiology|Neurology|Rare Disease
- Trial Disease
- Transthyretin amyloidosis | Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 14-07-2025
- First CTIS Authorization Date
- 22-10-2025
Trial design
open-label, none/not specified-controlled Phase III trial in Germany, Italy, Portugal and others.
- Open Label
- Yes
- Comparator
- None/Not specified
- Target Sample Size
- 155
Eligibility
Recruits 155 isVulnerablePopulationSelected is true. Inclusion criterion 2: "Participant must be willing and able to give signed informed consent for participation in the study. Informed consent must be obtained prior to initiation of study procedures." No provisions for assent or minor consent are specified in the available record..
- Pregnancy Exclusion
- 9. Female participants who are pregnant or breastfeeding. A negative urine pregnancy test on Day 1 prior to dosing is required for WOCBP. A positive urine dipstick pregnancy test will need to be confirmed with a serum test and participants cannot commence AG10-504 study unless the serum test results return negative.
- Vulnerable Population
- isVulnerablePopulationSelected is true. Inclusion criterion 2: "Participant must be willing and able to give signed informed consent for participation in the study. Informed consent must be obtained prior to initiation of study procedures." No provisions for assent or minor consent are specified in the available record.
Inclusion criteria
- {"criterion_text":"- 1. Participants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM)."}
- {"criterion_text":"- 2. Participant must be willing and able to give signed informed consent for participation in the study. Informed consent must be obtained prior to initiation of study procedures."}
- {"criterion_text":"- 3. Agree to the use of highly effective contraception: a. FEMALE: WOCBP (defined as all women physiologically capable of becoming pregnant) who engage in heterosexual intercourse must agree to use a highly effective method of contraception from Day 1 and continuing for 30 calendar days after the last dose of study drug. (see Section 8.3.6). b. MALE: A male participant who has not had a vasectomy and is sexually active with a female of childbearing potential must agree to use a double-barrier method of birth control during the study and continue for 30 calendar days after the last dose of study drug. Males must agree to refrain from sperm donation for a minimum of 30 calendar days post the last dose of the study drug."}
Exclusion criteria
- {"criterion_text":"- 1. Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only or who permanently discontinued IMP prior to diagnosis of ATTR-CM in AG10-501."}
- {"criterion_text":"- 10. In the judgment of the Investigator or Medical Monitor, has any clinically relevant ongoing medical condition or laboratory abnormality or other condition that might jeopardize the participant’s safety, increase the participant’s risk from participation, interfere with the study, or confound study results."}
- {"criterion_text":"- 11. Participation in another investigational clinical trial. Participation in observational and/or registry studies must be discussed with the Medical Monitor."}
- {"criterion_text":"- 12. Major surgery planned during the next 6 months. For participants who may have required major surgery during their participation in the AG10-501 study and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 provided study participation does not interfere with the surgical care plan and vice versa."}
- {"criterion_text":"- 2. History of light-chain amyloidosis (AL) or another non-TTR amyloid subtype (eg, ApoA 1, gelsolin)."}
- {"criterion_text":"- 3. History of a monoclonal paraprotein or abnormal light chains in serum or urine (ie, MGUS) in which AL has not been ruled out."}
- {"criterion_text":"- 4. Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL/min/1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant."}
- {"criterion_text":"- 5. Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 after documentation with the Medical Monitor."}
- {"criterion_text":"- 6. History of any organ transplant (with the exception of corneal transplant)."}
- {"criterion_text":"- 7. Known hypersensitivity to acoramidis or any of the excipients within the study drug."}
- {"criterion_text":"- 8. Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product."}
- {"criterion_text":"- 9. Female participants who are pregnant or breastfeeding. A negative urine pregnancy test on Day 1 prior to dosing is required for WOCBP. A positive urine dipstick pregnancy test will need to be confirmed with a serum test and participants cannot commence AG10-504 study unless the serum test results return negative."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Proportion of participants with: treatment-emergent AEs and SAEs, AEs leading to treatment discontinuation, abnormal physical examination findings of clinical relevance, abnormal vital signs of clinical relevance, abnormal ECG parameters ofclinical relevance, changes in clinical safety laboratory parameters of potential concern","definition_or_measurement_approach":"Proportion of participants experiencing each listed safety outcome during treatment (treatment-emergent adverse events [AEs], serious AEs [SAEs], AEs leading to discontinuation, clinically relevant abnormal physical exam findings, vital signs, ECG parameters, and changes in clinical safety laboratory parameters)."}
Secondary endpoints
- {"endpoint_text":"- 1. All-cause mortality and cardiovascular mortality","definition_or_measurement_approach":"Assessment of deaths classified as all-cause and cardiovascular mortality (as stated)."}
- {"endpoint_text":"- 2. Cardiovascular-related hospitalization","definition_or_measurement_approach":"Occurrence/count of hospitalizations related to cardiovascular causes (as stated)."}
- {"endpoint_text":"- 3. Participants with: • Any HF event: O-HF and/or UV-HF and/or H-HF • UV-HF and/or H-HF • O-HF • UV-HF • H-HF • NOHF","definition_or_measurement_approach":"Recording of predefined heart failure (HF) events: outpatient HF event (O-HF), urgent visit for HF (UV-HF), hospitalization for HF (H-HF), and new onset HF (NOHF) as listed."}
- {"endpoint_text":"- 4. Development of symptomatic ATTR-CM as defined by the investigator","definition_or_measurement_approach":"Investigator-defined development of symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM)."}
- {"endpoint_text":"- 5. New arrhythmia and cardiac conduction complications (not otherwise attributable to a non-amyloid cause) as defined by: • New onset of atrial fibrillation or atrial flutter and/or • Sustained ventricular tachycardia or sudden cardiac death and/or • New onset 1st or 2nd degree atrioventricular block and/or • Conduction disease requiring temporary transvenous or permanent pacemaker implantation","definition_or_measurement_approach":"Identification of new arrhythmias or conduction disorders meeting the listed criteria (new AF/flutter, sustained VT or SCD, new 1st/2nd degree AV block, conduction disease requiring pacemaker)."}
- {"endpoint_text":"- 6. New diagnosis of or therapeutic surgery (not otherwise attributable to a non-amyloid cause) for: • Carpal tunnel syndrome and/or • Brachial biceps tendon rupture or Achilles tendon rupture and/or • Lumbar spinal stenosis and/or • Hip and knee osteoarthritis and/or • Trigger finger and/or • Rotator cuff osteoarthritis","definition_or_measurement_approach":"Recording of new diagnoses or surgeries for listed musculoskeletal conditions not otherwise attributable to non-amyloid causes."}
- {"endpoint_text":"- 7. Change from baseline in: o Echocardiographic and strain parameters that estimate myocardial structure and function o NT-proBNP and hsTnI","definition_or_measurement_approach":"Change from baseline for echocardiographic and strain parameters and biomarker levels (NT-proBNP, hsTnI)."}
Recruitment
- Planned Sample Size
- 155
- Recruitment Window Months
- 77
- Consent Approach
- "Participant must be willing and able to give signed informed consent for participation in the study. Informed consent must be obtained prior to initiation of study procedures." Subject information and ICF documents (including a Pregnant Participant ICF and materials in multiple languages) are provided; consent is signed by participant prior to study procedures. No assent procedures for minors are described.
Methods
- Rollover recruitment from participants who completed the AG10-501 study (ACT-EARLY); inclusion criterion requires participants to have completed AG10-501 within the past 60 calendar days.
Geography
- Total Number Of Sites
- 34
- Total Number Of Participants
- 117
Germany
- Earliest CTIS Part Ii Submission Date
- 06-10-2025
- Latest Decision Or Authorization Date
- 28-10-2025
- Processing Time Days
- 22
- Number Of Sites
- 3
- Number Of Participants
- 9
Sites
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Klinik für Kardiologie, Angiologie und Intensivsmedizin
- Principal Investigator Name
- Katrin Hahn
- Principal Investigator Email
- katrin.hahn@charite.de
- Contact Person Name
- Katrin Hahn
- Contact Person Email
- katrin.hahn@charite.de
- Site Name
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
- Department Name
- Studienzentrum der Klinik und Poliklinik für Neurologie
- Principal Investigator Name
- Frank Birklein
- Principal Investigator Email
- frank.birklein@unimedizin-mainz.de
- Contact Person Name
- Frank Birklein
- Contact Person Email
- frank.birklein@unimedizin-mainz.de
- Site Name
- Universitaetsklinikum Heidelberg AöR
- Department Name
- Neurologische Klinik
- Principal Investigator Name
- Markus Weiler
- Principal Investigator Email
- markus.weiler@med.uni-heidelberg.de
- Contact Person Name
- Markus Weiler
- Contact Person Email
- markus.weiler@med.uni-heidelberg.de
Italy
- Earliest CTIS Part Ii Submission Date
- 01-08-2025
- Latest Decision Or Authorization Date
- 27-10-2025
- Processing Time Days
- 87
- Number Of Sites
- 7
- Number Of Participants
- 20
Sites
- Site Name
- Azienda Ospedaliera Universitaria Gaetano Martino Messina
- Department Name
- Neurology
- Principal Investigator Name
- Anna Mazzeo
- Principal Investigator Email
- annamazzeo@yahoo.it
- Contact Person Name
- Anna Mazzeo
- Contact Person Email
- annamazzeo@yahoo.it
- Site Name
- Fondazione Toscana Gabriele Monasterio
- Department Name
- Cardiology
- Principal Investigator Name
- Alberto Aimo
- Principal Investigator Email
- aimoalb@ftgm.it
- Contact Person Name
- Alberto Aimo
- Contact Person Email
- aimoalb@ftgm.it
- Site Name
- Fondazione IRCCS Policlinico San Matteo
- Department Name
- rare diseases
- Principal Investigator Name
- Laura Piera Obici
- Principal Investigator Email
- l.obici@smatteo.pv.it
- Contact Person Name
- Laura Piera Obici
- Contact Person Email
- l.obici@smatteo.pv.it
- Site Name
- Azienda Ospedaliero-Universitaria Sant Andre
- Department Name
- Neurology
- Principal Investigator Name
- Luca Leonardi
- Principal Investigator Email
- leonardi.luca89@gmail.com
- Contact Person Name
- Luca Leonardi
- Contact Person Email
- leonardi.luca89@gmail.com
- Site Name
- Azienda Ospedaliero Universitaria Careggi
- Department Name
- Cardiology
- Principal Investigator Name
- Francesco Cappelli
- Principal Investigator Email
- f.cappelli@unifi.it
- Contact Person Name
- Francesco Cappelli
- Contact Person Email
- f.cappelli@unifi.it
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Cardiology
- Principal Investigator Name
- Simone Longhi
- Principal Investigator Email
- simone.longhi@aosp.bo.it
- Contact Person Name
- Simone Longhi
- Contact Person Email
- simone.longhi@aosp.bo.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Neurology
- Principal Investigator Name
- Marco Luigetti
- Principal Investigator Email
- marco.luigetti@policlinicogemelli.it
- Contact Person Name
- Marco Luigetti
- Contact Person Email
- marco.luigetti@policlinicogemelli.it
Portugal
- Earliest CTIS Part Ii Submission Date
- 01-08-2025
- Latest Decision Or Authorization Date
- 23-10-2025
- Processing Time Days
- 83
- Number Of Sites
- 2
- Number Of Participants
- 11
Sites
- Site Name
- Unidade Local De Saude De Santa Maria E.P.E.
- Department Name
- Department of Neurosciences
- Principal Investigator Name
- Isabel Conceição
- Principal Investigator Email
- imsconceicao@gmail.com
- Contact Person Name
- Isabel Conceição
- Contact Person Email
- imsconceicao@gmail.com
- Site Name
- Unidade Local De Saude De Santo Antonio E.P.E.
- Department Name
- Neurophysiology Department
- Principal Investigator Name
- Márcio Cardoso
- Principal Investigator Email
- marciocardoso.neurofisiologia@chporto.min-saude.pt
- Contact Person Name
- Márcio Cardoso
- Contact Person Email
- marciocardoso.neurofisiologia@chporto.min-saude.pt
Netherlands
- Earliest CTIS Part Ii Submission Date
- 03-10-2025
- Latest Decision Or Authorization Date
- 24-10-2025
- Processing Time Days
- 21
- Number Of Sites
- 3
- Number Of Participants
- 3
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Cardiology
- Principal Investigator Name
- Michelle Michels
- Principal Investigator Email
- m.michels@erasmusmc.nl
- Contact Person Name
- Michelle Michels
- Contact Person Email
- m.michels@erasmusmc.nl
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Cardiology
- Principal Investigator Name
- Marish Oerlemans
- Principal Investigator Email
- m.oerlemans@umcutrecht.nl
- Contact Person Name
- Marish Oerlemans
- Contact Person Email
- m.oerlemans@umcutrecht.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Internal Medicine
- Principal Investigator Name
- Hans Nienhuis
- Principal Investigator Email
- h.l.a.nienhuis@umcg.nl
- Contact Person Name
- Hans Nienhuis
- Contact Person Email
- h.l.a.nienhuis@umcg.nl
Ireland
- Earliest CTIS Part Ii Submission Date
- 26-09-2025
- Latest Decision Or Authorization Date
- 31-10-2025
- Processing Time Days
- 35
- Number Of Sites
- 2
- Number Of Participants
- 3
Sites
- Site Name
- Tallaght University Hospital
- Department Name
- Neurology
- Principal Investigator Name
- Sinead Murphy
- Principal Investigator Email
- Sinead.murphy@tuh.ie
- Contact Person Name
- Sinead Murphy
- Contact Person Email
- Sinead.murphy@tuh.ie
- Site Name
- Mater Misericordiae University Hospital
- Department Name
- Cardiology
- Principal Investigator Name
- Emer Joyce
- Principal Investigator Email
- emerjoyce@mater.ie
- Contact Person Name
- Emer Joyce
- Contact Person Email
- emerjoyce@mater.ie
France
- Earliest CTIS Part Ii Submission Date
- 18-09-2025
- Latest Decision Or Authorization Date
- 12-12-2025
- Processing Time Days
- 85
- Number Of Sites
- 6
- Number Of Participants
- 24
Sites
- Site Name
- CHU De Martinique
- Department Name
- cardiology
- Principal Investigator Name
- Jocelyn Inamo
- Principal Investigator Email
- Inamo_jocelyn@yahoo.com
- Contact Person Name
- Jocelyn Inamo
- Contact Person Email
- Inamo_jocelyn@yahoo.com
- Site Name
- Bicetre Hospital
- Department Name
- Nephrology
- Principal Investigator Name
- Andoni Echaniz-Laguna
- Principal Investigator Email
- andoni.echaniz-laguna@aphp.fr
- Contact Person Name
- Andoni Echaniz-Laguna
- Contact Person Email
- andoni.echaniz-laguna@aphp.fr
- Site Name
- Pellegrin Hospital
- Department Name
- Neurology
- Principal Investigator Name
- Guilhem Sole
- Principal Investigator Email
- Guilhem.sole@chu-bordeaux.fr
- Contact Person Name
- Guilhem Sole
- Contact Person Email
- Guilhem.sole@chu-bordeaux.fr
- Site Name
- CHU de Rennes
- Department Name
- cardiology
- Principal Investigator Name
- Erwan Donal
- Principal Investigator Email
- erwan.donal@chu-rennes.fr
- Contact Person Name
- Erwan Donal
- Contact Person Email
- erwan.donal@chu-rennes.fr
- Site Name
- AP HP Hopital Henri Mondor
- Department Name
- cardiology
- Principal Investigator Name
- Thibaud Damy
- Principal Investigator Email
- thibaud.damy@aphp.fr
- Contact Person Name
- Thibaud Damy
- Contact Person Email
- thibaud.damy@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- cardiology
- Principal Investigator Name
- Olivier Lairez
- Principal Investigator Email
- lairez.o@chu-toulouse.fr
- Contact Person Name
- Olivier Lairez
- Contact Person Email
- lairez.o@chu-toulouse.fr
Sweden
- Earliest CTIS Part Ii Submission Date
- 29-01-2026
- Latest Decision Or Authorization Date
- 20-02-2026
- Processing Time Days
- 22
- Number Of Sites
- 1
- Number Of Participants
- 6
Sites
- Site Name
- Region Vaesterbotten (Umea University)
- Department Name
- Norrlands Universitetssjukhus, Amyloidosis center E41, Forsorjningsvagen 1 C, 901 85, Umeå, Sweden
- Principal Investigator Name
- Jonas Wixner
- Principal Investigator Email
- Jonas.wixner@umu.se
- Contact Person Name
- Jonas Wixner
- Contact Person Email
- Jonas.wixner@umu.se
Spain
- Earliest CTIS Part Ii Submission Date
- 02-10-2025
- Latest Decision Or Authorization Date
- 14-01-2026
- Processing Time Days
- 104
- Number Of Sites
- 6
- Number Of Participants
- 22
Sites
- Site Name
- Bellvitge University Hospital
- Department Name
- Cardiology
- Principal Investigator Name
- José González Costello
- Principal Investigator Email
- jgonzalez@bellvitgehospital.cat
- Contact Person Name
- José González Costello
- Contact Person Email
- jgonzalez@bellvitgehospital.cat
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Cardiology
- Principal Investigator Name
- Rocío Eiros Bachiller
- Principal Investigator Email
- eirosbachiller@gmail.com
- Contact Person Name
- Rocío Eiros Bachiller
- Contact Person Email
- eirosbachiller@gmail.com
- Site Name
- Hospital Universitario Juan Ramon Jimenez
- Department Name
- Internal Medicine
- Principal Investigator Name
- Cristina Borrachero Garro
- Principal Investigator Email
- crborrachero@gmail.com
- Contact Person Name
- Cristina Borrachero Garro
- Contact Person Email
- crborrachero@gmail.com
- Site Name
- Hospital Son Llatzer
- Department Name
- Internal Medicine
- Principal Investigator Name
- Juan González-Moreno
- Principal Investigator Email
- jgonzalez4@hsll.es
- Contact Person Name
- Juan González-Moreno
- Contact Person Email
- jgonzalez4@hsll.es
- Site Name
- Hospital Universitario Puerta De Hierro De Majadahonda
- Department Name
- Cardiology
- Principal Investigator Name
- Esther González López
- Principal Investigator Email
- esthgonzalez@hotmail.com
- Contact Person Name
- Esther González López
- Contact Person Email
- esthgonzalez@hotmail.com
- Site Name
- Complexo Hospitalario Universitario A Coruna
- Department Name
- Cardiology
- Principal Investigator Name
- Roberto Barriales Villa
- Principal Investigator Email
- roberto.barriales.villa@sergas.es
- Contact Person Name
- Roberto Barriales Villa
- Contact Person Email
- roberto.barriales.villa@sergas.es
Denmark
- Earliest CTIS Part Ii Submission Date
- 29-01-2026
- Latest Decision Or Authorization Date
- 06-03-2026
- Processing Time Days
- 36
- Number Of Sites
- 1
- Number Of Participants
- 2
Sites
- Site Name
- Region Midtjylland
- Department Name
- Cardiology
- Principal Investigator Name
- Torsten Rasmussen
- Principal Investigator Email
- torasm@rm.dk
- Contact Person Name
- Torsten Rasmussen
- Contact Person Email
- torasm@rm.dk
Greece
- Earliest CTIS Part Ii Submission Date
- 27-11-2025
- Latest Decision Or Authorization Date
- 02-02-2026
- Processing Time Days
- 67
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Hippokration Hospital
- Department Name
- 1st Cardiology Department, National and Kapodistrian University of Athens
- Principal Investigator Name
- Charalambos Vlachopoulos
- Principal Investigator Email
- ekkan@med.uoa.gr
- Contact Person Name
- Charalambos Vlachopoulos
- Contact Person Email
- ekkan@med.uoa.gr
- Site Name
- General Hospital Of Athens Alexandra
- Department Name
- Center of Expertise in Amyloidosis,Plasma Cell Dyscrasias U/Hem-Onc U,Dpt Clinical Ther,Med Sch NKUA
- Principal Investigator Name
- Efstathios Kastritis
- Principal Investigator Email
- ekastritis@med.uoa.gr
- Contact Person Name
- Efstathios Kastritis
- Contact Person Email
- ekastritis@med.uoa.gr
Belgium
- Earliest CTIS Part Ii Submission Date
- 30-01-2026
- Latest Decision Or Authorization Date
- 13-03-2026
- Processing Time Days
- 42
- Number Of Sites
- 1
- Number Of Participants
- 7
Sites
- Site Name
- UZ Leuven
- Department Name
- Neurology
- Principal Investigator Name
- Kristl Claeys
- Principal Investigator Email
- kristl.claeys@uzleuven.be
- Contact Person Name
- Kristl Claeys
- Contact Person Email
- kristl.claeys@uzleuven.be
Sponsor
Primary sponsor
- Full Name
- Eidos Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Medpace Ellas Monoprosopi I.K.E.
- Responsibilities
- Sponsor duties (codes 1, 12)
- Name
- Eresearchtechnology Inc. (Clario)
- Responsibilities
- Central ECG Reader
- Name
- United Biosource LLC
- Responsibilities
- Safety database management
- Name
- Almac Clinical Services LLC
- Responsibilities
- IVRS & Randomization, IP Depot Distribution and Packaging
- Name
- Medpace Finland Oy
- Responsibilities
- Safety labs, sample management and related services
Third parties
- {"country":"Greece","full_name":"Medpace Ellas Monoprosopi I.K.E.","duties_or_roles":"sponsorDuties codes: 1, 12","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"Central ECG Reader","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"United Biosource LLC","duties_or_roles":"safety database","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Almac Clinical Services LLC","duties_or_roles":"IVRS & Randomization, IP Depot Distribution and Packaging; other duties (codes 14,3,15)","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Allucent (US) LLC","duties_or_roles":"Data Flow Mapping for GDPR","organisation_type":"Pharmaceutical company"}
- {"country":"Finland","full_name":"Medpace Finland Oy","duties_or_roles":"Safety Labs, sample management; other sponsor duties (codes 1,12,15,4)","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- Acoramidis (AG10)
- Active Substance
- acoramidis hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Maximum Dose
- 1424 mg
Related trials
Other published trials that may interest you.